Ensemble Therapeutics

Engineering synthetic macrocycle drugs with a focus on Immune Checkpoint and Ubiquitin Proteasome Inhibitors

placeCambridge, Massachusetts, United States calendar_todayFounded 2004 groups35 employees language ensembletx.com

Registered entities

Investor mix

5 investors on record; lead investors include Arch Venture Partners, Oxford Bioscience Partners, Flagship Pioneering.

Investor typeCountShare
Venture capital5100%
Coming soon